次新異動 | 再現翻倍股!力高健康生活上市次日漲超50%,2日股價翻倍
繼上市首日收漲26%後,次新股力高健康生活上市第二日繼續強勢拉昇,最高價報8.28港元,漲幅60%,最新市值16.24億港元。上市以來累計最高漲幅102%,一手賬面賺2090港元。
該公司爲江西省領先的物業管理服務供應商,服務網絡涵蓋長江三角洲地區、大灣區、環渤海地區及華中地區等具有策略意義的核心區域。截至2021年9月30日,公司的在管項目總計達91個,在管總建築面積達1510萬平方米,並且已訂約管理位於中國11個省、市及自治區的28座城市的133個項目,合約總建築面積爲2350萬平方米。上市將構成力高集團的分拆。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.